ArticleTargeted oncology2024

A Phase 1a/1b Dose Escalation/Expansion Study of the Anti-PD-1 Monoclonal Antibody Nofazinlimab in Chinese Patients with Solid Tumors or Lymphoma.

Jifang Gong et al.PubMed ↗Publisher ↗

No numbers read from the abstract.